Serum interleukin-2 receptor levels in Hodgkin disease and other solid tumors of childhood.
Serum levels of interleukin-2 receptor (IL2R) were determined in children with newly diagnosed Hodgkin disease (n = 68), Wilms tumor (n = 20), osteosarcoma (n = 18), rhabdomyosarcoma (n = 18), or Ewing sarcoma (n = 15). Measurements of soluble IL2R were positively correlated with disease stage in Hodgkin disease but not in other tumors. Very high levels of soluble IL2R (> or = 5000 U/ml) were significantly associated with a poorer treatment outcome in Hodgkin disease (p = 0.006) and retained significance in a multivariate analysis (p = 0.03). The addition of soluble IL2R measurements to existing prognostic models may improve risk assignment in children with Hodgkin disease.
Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101.
C H
CH
Pui
M
M
Hudson
X
X
Luo
J
J
Wilimas
W
W
Evans
W M
WM
Crist
D002648:Child; D006689:Hodgkin Disease / Q000097:blood* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009369:Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D012516:Osteosarcoma / Q000097:blood; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D012044:Regression Analysis; D012208:Rhabdomyosarcoma / Q000097:blood; D012512:Sarcoma, Ewing / Q000097:blood; D012995:Solubility; D009396:Wilms Tumor / Q000097:blood
D015375:Receptors, Interleukin-2